Collegium Announcements: Leadership Reshuffle and Board Updates
Portfolio - People | Mar 17, 2025 | EIN
Collegium Pharmaceutical, a biopharmaceutical company, has announced a series of leadership changes in its board of directors and executive team. The changes aim at driving a new growth phase, with the founder and chairman, Michael Heffernan, and board member, Gwen A. Melincoff, scheduled to retire in May 2025. Gino Santini, the company's lead independent director, will ascend to chairman, and Dr. Carlos Paya has been nominated for the board, pending shareholder approval. Newly appointed executives— David Dieter as Executive Vice President, General Counsel, Jane Gonnerman as Executive Vice President of Strategy and Corporate Development, and Dean J. Patras as Chief People Officer—join Collegium as it aims to advance its mission in treating serious medical conditions. The company is focusing on accelerating growth for its ADHD treatment, Jornay PM, and expanding its responsible pain management portfolio.
Sectors
- Biopharmaceuticals
- Healthcare
Geography
- United States – Collegium Pharmaceutical is based in Stoughton, Massachusetts, highlighting its operations within the US.
Industry
- Biopharmaceuticals – Collegium Pharmaceutical operates within the biopharmaceutical industry, focusing on developing treatments for serious medical conditions like ADHD and responsible pain management.
- Healthcare – The healthcare sector is relevant to the article because it encompasses companies that provide medical services, manufacture medical equipment or drugs, and facilitate the provision of these services and products.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Target | Company | A biopharmaceutical company focusing on responsible pain management and neuropsychiatry. |
| Michael Heffernan | Outgoing Chairman | Person | Founder and Chairman of Collegium, retiring in May 2025. |
| Gwen A. Melincoff | Outgoing Board Member | Person | Board member retiring in May 2025. |
| Gino Santini | Incoming Chairman | Person | Lead Independent Director, becoming Chairman in May 2025. |
| Dr. Carlos Paya | Board Nominee | Person | Nominated to join Collegium's Board, experienced in the biopharmaceutical industry. |
| David Dieter | Executive Vice President, General Counsel | Person | Appointed to provide legal expertise to Collegium as part of the leadership changes. |
| Jane Gonnerman | Executive Vice President, Strategy and Corporate Development | Person | Part of Collegium's new executive team focusing on strategic growth. |
| Dean J. Patras | Chief People Officer | Person | Newly appointed to lead human resources at Collegium. |